🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to scientists.

An International Challenge

The sexually transmitted infection are increasing globally, with estimates suggesting in excess of 82 million new cases each year. Notably increased rates are reported in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Health officials are increasingly worried about the rise in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Recent surveillance found that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This infection can lead to major issues, including infertility. Scientists anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, also received approval in concurrent days. This medication, which is additionally indicated for urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to results published in a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This puts it on an similar efficacy with the current standard treatment, which involves an injection and a pill. The trial included nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the ability to license and sell the drug in numerous low-income and middle-income countries.

Doctors directly involved have expressed positive views. Having a easy-to-administer therapy like this is hailed as a "revolutionary step" for managing the epidemic. This is deemed essential to alleviate the strain of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea globally.